Trident Lifeline Ltd. · BSE:TLL
Trident Lifeline — H1 FY2024 Earnings Presentation
31 slides from Trident Lifeline's earnings presentation, Nov 7, 2023
Slide 1: Regulation 30 cover letter to BSE: Earnings Presentation H1FY24
It Ti=:I.IDENT™ CIN No. : L51909GJ2014PLC078227 GST No. : 24AAECT8906D1ZG ~ LIFELINE TRIDENT LIFELINE LIMITED (Formerly Trident Lifeline Private Limited) Date: 07th November, 2023 BSE Limited Stock ID: TLL 14th Floor, P. J. Towers, Scrip Code: 543616 Dalal Street, Fort, Mumbai - 400001. Sub: Earning
Slide 2: H1FY24 Presentation
H1FY24 Presentation Tr i d e n t L i f e l i n e L i m i t e d November 2023
Slide 3: Inside the document
Inside the document Pg. 03 __ Company Over view Pg. 09 __ Expansive Product Portfolio Pg. 13 __ Global Footprint Pg. 17 __ Leadership Pg. 18 __ Strategy & Investment Rationale Pg. 23 __ Financials & Management Commentar y
Slide 4: Company Overview
| i 9 Company || Overview
Slide 5: Introduction to Trident Lifeline
Introduction to Trident Lifeline About us A growing force in pharmaceutical Trident Lifeline Limited (“Trident formulations export. Vision Lifeline” or “the Company”) 537 1,279 29 To be a leading is a diversified pharmaceutical pharmaceutical company Company with business globally by providing high-
Slide 6: Superior Business Model
Superior Business Model A growing force in 537 1,279 29 pharmaceutical Export market Export market product Countries present formulations products registered registrations in process in globally export Asset-light Asset-light State-of-art Strategic M&A third-party contract Contract manufacturing mod
Slide 7: Presence across Value Chain
Presence across Value Chain Procurement Manufacturing Exports Sales & Marketing Complete control over supply- • Third-party contract • Engaged in direct exports • Dedicated sales & marketing chain, procurement done by manufacturing under own brands & product team for branded sales Trident Lifeline i
Slide 8: Strengthening Presence Across Value Chain
Strengthening Presence Across Value Chain Strategic Acquisition of TNS Pharma Private Limited Upcoming Manufacturing Capacity at TNS Tablets: 6 Crore Monthly 51% Total Equity Stake Acquired November’23 Expected Commissioning of Manufacturing Facility Capsules: Dry Powder: Sachin GIDC Classified as a
Slide 9: Strengthening Presence Across Value Chain (continued)
Strengthening Presence Across Value Chain (continued) Strategic Acquisition of Strategic Acquisition of TLL Herbal Limited Tricorp Industries Limited 51% Total Equity Stake Acquired 18% Total Equity Stake Acquired on 10th August 2023 In the business of herbal In the business of intermediates product
Slide 10: Expansive Product Portfolio
Expansive Product Portfolio
Slide 11: Expansive Product Portfolio
Expansive Product Portfolio The Company’s growing portfolio of products spans over Product categories ▸ Anti Bacterial ▸ Anti Diarrheal ▸ Anti Fungal ▸ Anti Malarial ▸ Anti Diabetic ▸ Dental Cure ▸ Proton Pump Inhibitor ▸ Anti Protozoal Product Categories ▸Anti Histamine 12 ▸Anti Hypertensive drugs
Slide 12: Expansive Product Portfolio (continued)
Expansive Product Portfolio (continued) The Company’s growing portfolio of products spans over Product categories ▸ Capsule ▸ Tablet ▸ Liquid Ointment ▸ Gel ▸ Ice Gel ▸ Mouthwash Product Categories ▸ Paste 12 ▸ Solution ▸ Suspension ▸ Toothpaste Therapeutic Categories 16 ▸ Syrup ▸ Cream 2 PRODUCT PO
Slide 13: Revenue Break-up: Product Categories
Expansive Product Portfolio (continued) Revenue Break-up: Product Categories Tablets are by far the largest product category (In %) accounting for 63% of the revenue 0 6 6 7 Followed by capsules being the second largest 21 9 9 23 3 5 category which accounts for 17% of the revenue. 4 0 Other categori
Slide 14: Expansive Product Portfolio (continued)
Expansive Product Portfolio (continued) 4 PRODUCT PORTFOLIO Trident Lifeline Limited | 13
Slide 15: Growing Global Footprint
Growing Global Footprint
Slide 16: Growing Geographical Footprint
Growing Geographical Footprint Trident Lifeline has a growing geographical footprint and a formidable presence export markets such as African, Latin American, CIS and East Asian Uzbekistan countries. Tajikistan 12 Venezuela UAE Sudan India Myanmar Vietnam Cambodia Countries where products are regist
Slide 17: Geographical Revenue Mix
Geographical Revenue Mix Being an export-oriented The share of exports • Africa is a major export market for the Other key markets for the Company, Trident has been have increased from company Company include constantly increasing the 55% in FY20 to 76% • Followed by increasing share in Asian • Indi
Slide 18: Bolstering Export Growth
Bolstering Export Growth Trident Lifeline has been making Export product registrations are consistent, upfront investments in a painstaking task, involving export product registrations to significant gestation period bolster revenue growth of 1.5 to 3 years. The Company also needs to register Till d
Slide 19: Bolstering Export Growth (continued)
Bolstering Export Growth (continued) Country-wise product bifurcation Ghana, Venezuela, Cambodia (In %) & Kenya combined accounts Ghana 421 Kuwait 30 for ~60% the total product Venezuela 239 DR Congo 28 registered and under registration. Cambodia 200 Myanmar 28 Kenya 172 Others 160 Peru 153 Jordan 2
Slide 20: Leadership
Q ‘c LY Yo O xe) O O —I
Slide 21: Board of Directors
Board of Directors Mr. Hardik Jigishkumar Desai Mr. Shravan Harikrishna Patel Mr. Mayurkumar Mansukhbhai Gajera Mr. Hardik Jigishkumar aged 45 years is Mr. Shravan Harikrishna Patel aged 29 years is Mr. Mayurkumar Mansukhbhai Gajera aged 38 Promoter-Chairman and Executive Director of Managing Direct
Slide 22: Strategy & Investment Rationale
Strategy & Investment Rationale
Slide 23: Strategic Priorities
Strategic Priorities Continuous Expanding investments in intellectual Building sales & Strengthening Expand product product property marketing supply chain portfolio registrations registrations prowess • 300-400 additional • Registering brand’s • Strengthening strategic • Expanding dedicated • Grow
Slide 24: Investment Rationale
Investment Rationale • Trident’s business model reaps • 1,279 registrations in pipeline spread backloaded investment Extensive over 29 countries, with many benefits of product Exponential registrations under advance stages registrations product of the approval growth registrations • Current product
Slide 25: Financials & Management Commentary
Financials & Management Commentary
Slide 26: Half-Yearly Profit & Loss Snapshot
Half-Yearly Profit & Loss Snapshot (₹ in Lakh) Particulars H1FY24 H2FY23 H1FY23 YOY Change (%) +38% YOY Revenue growth in H1FY24 Total Revenue 1928.38 1889.69 1395.34 38% Total Operating Expenses 1,462.03 1,393.72 1,150.42 27% EBITDA 466.35 495.97 244.92 90% EBITDA (%) 24% 26% 18% 663 BPS +90% YOY I
Slide 27: Management Commentary
Management Commentary • Trident Lifeline continues to build on its robust financial performance by reporting a top line of 1,928.38 Lakhs for H1FY24, recording an increase of 38% YOY and 2% on QOQ. • EBITDA margin remained robust at 24% in H1FY24, as opposed to 26% in H2FY23 and 18% in H1FY23. EBITD
Slide 28: Annual Profit & Loss Snapshot
Annual Profit & Loss Snapshot (₹ in Lakh) Particulars FY20 FY21 FY22 FY23 Total Revenue 505.63 978.12 2,237.14 3285.02 Total Operating Expenses 517.2 836.93 1,905.94 2544.14 EBITDA -11.57 141.2 331.2 740.88 EBITDA (%) -2% 14% 15% 23% Interest Cost 76.21 41.23 12.58 46.59 Depreciation & Amortisation
Slide 29: Balance Sheet Snapshot
Balance Sheet Snapshot (₹ in Lakh) Particulars FY20 FY21 FY22 FY23 H1FY24 Shareholders Fund -500.31 -217.21 477.57 4563.49 4867.08 Non Current Liability 646.93 457.65 148.94 226.08 271.22 Current Liabilities 286.65 735.61 756.98 1094.90 1171.96 Other Current Liabilities 103.24 333.81 234.10 613.82 5
Slide 30: Cash Flow Snapshot
Cash Flow Snapshot (₹ in Lakh) Particulars FY20 FY21 FY22 FY23 H1FY24 Cash from Operating Activities -81.86 -32.02 -21.47 -1659.93 -152.91 Cash from Investing Activities -13.63 24.79 -44.52 -556.00 -443.54 Cash from Financing Activities 103.75 1.43 80.19 3580.08 23.99 Net Cash Flow 8.26 -5.8 14.20 1
Slide 31: Safe Harbour
Safe No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all events not current after the date of